United Kingdom
An experienced Cell & Gene Therapy Senior Leader and Board Member with a strong track record of leadership and teamwork in developing and commercialising innovative advanced therapies. My focus is on delivering positive ethical outcomes for patients and customers by utilising a commercially-minded and pragmatic approach to advanced therapy development. As a pharmaceutical physician and clinician I have extensive surgical and medical clinical experience with a strong patient focus. Additional Positions: Xintela AB (Sweden) - Board Member and Interim CMO & COO CCRM (Canada) - Board Member and Investment Committee member BIA Cell & Gene Advisory Committee Chair Standards Coordinating Body - Executive Board Member Senior Medical and business strategic expertise focussed on extensive Clinical Development and Medical Affairs expereince involving a broad range of activities including: Ethical promotion of Medicines and Devices (UK, EU, US, Asia, Australia); Clinical research (phase II/ III/ IV) and product registration and reimbursement activities. Therapy area Expertise: Cell Based Therapies, including Gene Therapies and Gene Modified cells Stem Cells Cartilage repair and regeneration Joint resurfacing Bone repair and growth Rare Diseases Renal Medicine (CKD- pre and dialysis) Cardiovascular medicine (Familial Hypercholesterolemia) Medical devices Surgical disciplines (Orthopaedics, Reconstructive surgery, Urology, GI Surgery, Neurosurgery, Vascular surgery, Cardiothoracic surgery) Specialties: Biotech business company formation, management and strategy Medical Affairs Research and Development Drugs safety, Device Safety and pharmacovigilance - (EU QPPV experience) Regulatory Strategies for medicines and ATMP products Product aquisition and due diligence activities Practical training (internal and external) EU licence application activities (MAA CTD, RMP and PiP) Risk & crisis management and communication Market access planning (NICE, SMC, AWMSG)
Member of the BHF Translational Research Grants committee, focussing on accelerating exciting and innovative science to the clinic for the benefit of patients.
Boutique VC firm investing in transformative science and exceptional people to build great cell and gene therapy companies. We combine the best from Japan and The United States & Europe.
Chair of Hubs Steering committee, responsible for ensuring alignment and strategy for all Three Gene Therapy Hubs and working closely with Hubs directors, MRC and LifeArc teams to deliver on milestones.
I support Small and Medium-sized CGT and Regen Med companies to grow thoughtfully and optimise their Strategy, capabilities and Product Development with an unwavering focus on the patient. Areas of focus include: Company creation, build out and financing Translation of technology into actionable and developable therapies Strategic Direction setting and optimisation of technology strengths Clinical Development planning and execution with the patient in mind Late stage development, commercialisation preparation and launch effectiveness Post-Marketing Patient-centric Medical and Clinical strategic support
https://www.ucl.ac.uk/biochemical-engineering/study/postgraduate-taught/manufacture-and-commercialisation-stem-cell-and-gene-therapies-msc Chairman of Steering Committee for UCL Masters Programme in "Manufacture and Commercialisation of Stem Cell and Gene Therapies"